Company Quick10K Filing
Nanovibronix
10-Q 2019-09-30 Filed 2019-11-19
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-20
10-K 2018-12-31 Filed 2019-04-15
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-03-29
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-03-31
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-15
10-Q 2016-03-31 Filed 2016-05-16
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-14
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-03-30
8-K 2020-04-01 Other Events, Exhibits
8-K 2019-11-18 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-07-31 Enter Agreement, Sale of Shares, Shareholder Rights, Amend Bylaw, Exhibits
8-K 2019-06-21 Enter Agreement, Sale of Shares, Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Other Events, Exhibits
8-K 2019-06-13 Other Events, Exhibits
8-K 2019-05-29 Officers, Exhibits
8-K 2019-05-20
8-K 2019-05-10 Enter Agreement, Off-BS Arrangement
8-K 2019-03-29 Enter Agreement, Off-BS Arrangement, Sale of Shares
8-K 2019-03-14
8-K 2019-03-11 Regulation FD, Exhibits
8-K 2019-02-22 Enter Agreement, Sale of Shares
8-K 2019-02-05 Enter Agreement
8-K 2018-12-04 Other Events
8-K 2018-09-14
8-K 2018-08-16 Other Events, Exhibits
8-K 2018-07-04 Officers, Exhibits
8-K 2018-06-13 Officers, Shareholder Vote, Exhibits
8-K 2018-04-27 Accountant, Other Events, Exhibits
8-K 2018-04-19 Other Events
8-K 2018-04-02 Other Events, Exhibits

Nanovibronix Financials

NAOV Metrics, Comps, Filings

Quarterly | Annual

Business

-The delisting of our common stock from the NASDAQ Capital Market.

-The timing of clinical studies and eventual U.S. Food and Drug Administration approval of our product candidates.

-Regulatory actions that could adversely affect the price of or demand for our approved products.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Conformis (CFMS) 127,869 48% -4.3 -45% 73,289 53,389 79,589 37,949 -32,915 -27,325 117,871
Northern Technologies International (NTIC) 113,086 32% 16.5 8% 67,511 10,916 55,750 17,780 5,663 6,518 107,229
Invacare (IVC) 260,927 28% 75.7 -4% 847,405 531,926 939,627 262,330 -35,889 5,263 398,168
Lakeland Industries (LAKE) 96,208 34% 15.9 2% 99,104 14,863 79,620 27,271 2,076 5,578 88,423
Shiloh Industries (SHLO) 94,685 9% 7.8 -3% 651,691 484,177 1,054,707 90,576 -19,947 42,453 329,060
Virco Manufacturing (VIRC) 66,783 39% 4.8 5% 139,865 75,316 164,250 64,668 6,692 16,737 80,443
Precision Therapeutics (AIPT) 13,264 72% 105.9 0% 5,416 2,389 1,320 951 0 123 13,054
Alpha Pro Tech (APT) 48,716 37% 11.9 7% 37,864 4,621 35,746 13,130 2,665 3,665 43,610
Hudson Technologies (HDSN) 28,561 10% -18.2 -11% 204,206 149,253 162,027 15,484 -23,276 -6,358 116,006
Rewalk Robotics (RWLK) 23,214 54% -0.8 -42% 28,426 14,311 3,692 2,010 -11,976 -11,972 9,493
Nanovibronix (NAOV) 19,155 69% -3.7 -150% 3,070 840 443 307 -4,601 -4,568 16,897
Milestone Scientific (MLSS) 47,202 69% -10.0 -75% 6,243 7,647 6,074 4,179 -4,661 -4,564 45,491
Myomo (MYO) 13,064 73% -1.1 -131% 6,083 1,664 2,317 1,696 -7,952 -7,952 8,660
Industrial Services of America (IDSA) 9,385 1% -9.3 -13% 24,547 16,631 41,558 276 -3,228 -1,712 15,855
Allied Healthcare Products (AHPI) 8,790 17% -10.1 -10% 15,479 4,202 32,089 5,420 -1,489 -838 8,487
XPEL (XPEL) 35% -0.7 16% 47,406 17,347 65,712 22,899 7,517 10,348 -6,897
Predictive Oncology (POAI) 62% 0.0 -8% 31,882 11,168 1,064 664 -2,543 -2,060 -99
Ocugen (OCGN) 0.4 -150% 23,619 36,712 0 -900 -35,424 -34,628 -14,394
BRP (DOOO)
Steel Partners Holdings (SPLP) 32% 2.0 1% 2,345,718 1,828,035 1,197,598 388,309 33,977 151,171 301,966

Balance Sheet ($'000)2015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash2,2581,9941,6141,27879953210651215824,3603,4912,5151,7278961842,3712,258
Accounts Receivable14651171164329242370709570239175
Inventory53747176596367608291767878134144141102104
PP&E141211015141251108751681058665
Assets2,6292,3531,9831,6511,2379244944467578094,8653,9753,1732,4251,5808173,1073,070
Accounts Payable393958432869821232233571684076143193230343186
Long-Term Debt
Liabilities1,1571,8482,1922,2572,3972,5272,9933,2493,8085,0981,2311,0219531,6211,7571,2861,172840
Stockholders' Equity1,472505-209-606-1,160-1,603-2,499-2,803-3,051-4,2893,6342,9542,2201,386463-4691,9352,230
Income Statement ($'000)2015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue3940395762614952526570771445579263101
Cost of Revenue1510142722271116182232225546265654
Gross Profit2430253040343836364338558995320747
R&D1158710211417316113715016416021913615112215215079
SG&A2242813843903234187426878254968367099641,2132,124953761
Tax518191098911131151211111262
Net Income-434-1,039-781-495-610-606-1,120-877-849-1,599-1,641-789-14-1,344-2,679-1,107-815
Cash Flow ($'000)2015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-264-380-362-478-267-426-405-514-780-867-1,004-798-937-792-1,113
Cash Investing00-7-1000-22-2-3-3000
Cash Financing00330003506805,056031132252,9791,000